autologous AdE1-LMP cytotoxic T lymphocytes

Autologous AdE1-LMP cytotoxic T lymphocytes are an investigational adoptive cell therapy developed to treat Epstein-Barr virus (EBV)-associated malignancies and autoimmune conditions. The manufacturing process involves harvesting a patient's own peripheral blood mononuclear cells and expanding the T-cell population ex vivo using the AdE1-LMPpoly recombinant adenoviral vector. This vector is engineered to express a polyepitope comprising multiple HLA-restricted epitopes derived from the EBV latent membrane proteins 1 and 2 (LMP1 and LMP2), fused to a modified EBV nuclear antigen 1 (EBNA1) that lacks the glycine-alanine repeat to enhance MHC processing. By stimulating T cells with these specific viral antigens, the method generates a potent population of antigen-specific CD8+ cytotoxic T lymphocytes (CTLs). Upon re-infusion, these cells selectively target and lyse cells harboring the EBV genome, such as those in nasopharyngeal carcinoma, Hodgkin lymphoma, and multiple sclerosis, thereby bypassing the immune evasion strategies typically employed by the virus.

Other names

autologous EBV-specific cytotoxic T lymphocytesAdE1-LMP-specific CTLsAdE-1-LMP-specific CTLsAdE 1-LMP-specific CTLsAdE1-LMPpoly-expanded T cellsAdE-1-LMPpoly-expanded T cellsAdE 1-LMPpoly-expanded T cellsautologous AdE1-LMP CTLs